期刊
INTERNATIONAL IMMUNOPHARMACOLOGY
卷 11, 期 2, 页码 212-219出版社
ELSEVIER SCIENCE BV
DOI: 10.1016/j.intimp.2010.11.021
关键词
Paclitaxel; CD4+CD25+Foxp3+T cells; Bcl-2; Apoptosis; Lung cancer; Chemo-immunotherapy
资金
- National Key Technologies R & D Program of China [2009ZX10004-104, 2009ZX09301-011]
- National Science Foundation of China [30872378, J0730860]
- National 973 project in China [2010CB912603]
Paclitaxel has become one of the most effective and widely used chemotherapeutic agents over the past decades. Although it has shown promise to selectively deplete regulatory T (Treg) cells in our previous study, the underlying molecular mechanism remains to be further elucidated. The present study focused on the effect of paclitaxel on Treg cells in 3LL Lewis tumor model and explored the possible molecular pathways involved in this process. We found that paclitaxel significantly decreased the percentage of Treg cells in CD4(+) cells and impaired their suppressive functions, but effector T (Teff) cells remained unaffected. Compared with Teff cells, Treg cells exhibited a high sensitivity to paclitaxel-mediated apoptosis in vitro. Interestingly, though paclitaxel has been characterized as a mitotic inhibitor, tubulin was not involved in the selective function of paclitaxel. Treg cells exposed to paclitaxel displayed downregulation of Bcl-2 and upregulation of Bax. Blocking the Bcl-2 pathway eliminated the difference between Treg and Teff cells responding to paclitaxel. These results suggest that Bcl-2 rather than tubulin contributes to the distinctive effect of paclitaxel on Treg cells. Therefore, we here identify a molecular pathway through which paclitaxel selectively ablates Treg cells. (C) 2010 Elsevier B.V. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据